MILFORD, Mass. – SeraCare Life Sciences, Inc., a global life sciences company providing vital products and services to facilitate the discovery, development and production of human diagnostics and therapeutics, today announced that its Board of Directors has initiated a process to explore and evaluate potential strategic alternatives for the Company to enhance shareholder value, which may include a sale or other transaction.

As previously announced, Lazard is providing advisory services to the Board of Directors.

SeraCare has not made a decision to pursue any specific transaction or other strategic alternative, so there can be no assurance that the exploration of strategic alternatives will result in a sale of the Company or in any other transaction. There is no set timetable for the process. SeraCare does not intend to provide updates or make any further comments regarding the evaluation of strategic alternatives unless a specific transaction is recommended by the Board of Directors.

About SeraCare Life Sciences, Inc.:

SeraCare serves the global life sciences industry by providing vital products and services to facilitate the discovery, development and production of human diagnostics and therapeutics. SeraCare’s innovative portfolio includes diagnostic controls, plasma-derived reagents and molecular biomarkers, biobanking and contract research services. SeraCare’s quality systems, scientific expertise and state-of-the-art facilities support its customers in meeting the stringent requirements of the highly regulated life sciences industry.